JPET Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 11, 2006; DOI: 10.1124/jpet.106.102046


0022-3565/06/3181-173-185$20.00
JPET 318:173-185, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.102046v1
318/1/173    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galici, R.
Right arrow Articles by Conn, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galici, R.
Right arrow Articles by Conn, P. J.

NEUROPHARMACOLOGY

Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice

Ruggero Galici1, Carrie K. Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G. Echemendia, Lilly C. Williams, Tomas de Paulis, and P. Jeffrey Conn

Program in Translational Neuropharmacology, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee

Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. However, the relative contributions of the mGluR2 and mGluR3 subtypes to the effects of the group II mGluR agonists remain unclear. In the present study, we describe an alternate synthesis and further pharmacological characterization of a recently reported positive allosteric modulator of mGluR2 termed biphenyl-indanone A (BINA). In recombinant systems, BINA produced a robust and selective potentiation of the response of mGluR2 to glutamate with no effect on the glutamate response of other mGluR subtypes. In hippocampal brain slices, BINA (1 µM) significantly potentiated the mGluR2/3 agonist-induced inhibition of excitatory synaptic transmission at the medial perforant path-dentate gyrus synapse. BINA was also efficacious in several models predictive of antipsychotic- and anxiolytic-like activity in mice. The behavioral effects of BINA were blocked by the mGluR2/3 antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), suggesting that the in vivo effects of BINA are mediated by increased activation of mGluR2. Collectively, these results indicate that BINA is a selective mGluR2 positive allosteric modulator and provide further support for the growing evidence that selective allosteric potentiators of mGluR2 mimic many of the in vivo actions of mGluR2/3 agonists that may predict therapeutic utility of these compounds.


Received January 30, 2006; accepted March 24, 2006.

Address correspondence to: Dr. P. Jeffrey Conn, Professor, Director, Program in Translational Neuropharmacology, Department of Pharmacology, Vanderbilt University Medical Center, 23rd Ave. S. at Pierce, 417-D Preston Research Building, Nashville, TN 37232-6600. E-mail: jeff.conn{at}vanderbilt.edu




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane
Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia
J Psychopharmacol, May 1, 2008; 22(3): 308 - 322.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
Y. Chen, C. Goudet, J.-P. Pin, and P. J. Conn
N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors
Mol. Pharmacol., March 1, 2008; 73(3): 909 - 918.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. A. Benneyworth, Z. Xiang, R. L. Smith, E. E. Garcia, P. J. Conn, and E. Sanders-Bush
A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis
Mol. Pharmacol., August 1, 2007; 72(2): 477 - 484.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Hemstapat, H. Da Costa, Y. Nong, A. E. Brady, Q. Luo, C. M. Niswender, G. D. Tamagnan, and P. J. Conn
A Novel Family of Potent Negative Allosteric Modulators of Group II Metabotropic Glutamate Receptors
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 254 - 264.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, T. de Paulis, J.-P. Pin, and P. J. Conn
Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses
Mol. Pharmacol., May 1, 2007; 71(5): 1389 - 1398.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Hemstapat, T. de Paulis, Y. Chen, A. E. Brady, V. K. Grover, D. Alagille, G. D. Tamagnan, and P. J. Conn
A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators
Mol. Pharmacol., August 1, 2006; 70(2): 616 - 626.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.